Extension Of Substitution Approval For Shortage Of Catapres (clonidine) 150 Mcg Tablets

Catapres (Clonidine) 150 mcg Tablets Recall Summary The Therapeutic Goods Administration has extended approval for substituting Catapres (clonidine) 150 mcg tablets in Australia due to an anticipated shortage of the original product. This extension allows pharmacies and healthcare providers to continue supplying patients with an approved alternative during the shortage. The decision applies across Australia and affects anyone currently taking or prescribed this medication.

Reason

Serious Scarcity Substitution Instrument (SSSI) has lapsed and product is available.

Classification

Class III

Category

drug recall

Country

Australia

Agency

Therapeutic Goods Administration

Recall date

2026-04-28

Status

Ongoing

Distribution

Australia-wide

Official recall notice from Therapeutic Goods Administration

Recall details on Nibble Recalls: https://trynibble.app/recalls/b99e854b-d770-406b-ad52-121949c58d6b